Skip to main content

Sutro Biopharma, Inc.

STRO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001382101

No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Sutro Biopharma, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of STRO: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders138124−14
Shares44.4M41.2M−3.14M (−7.1%)
Value$1.01B$766.7M−$242.8M (−24.1%)

New holders (12)

Institutions that held Sutro Biopharma, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to STRO in Q2 2021
InstitutionSharesValue% of portfolio
Swiss National Bank70,800$1.32M0.00%
Principal Financial Group Inc67,809$1.26M0.00%
Balyasny Asset Management LLC61,432$1.14M0.01%
Los Angeles Capital Management LLC43,754$813.0K0.00%
Allianz Asset Management GmbH40,515$753.0K0.00%
Squarepoint Ops LLC34,877$648.0K0.00%
Hudson Bay Capital Management LP25,000$465.0K0.01%
Credit Suisse AG19,287$358.0K0.00%
Dynamic Technology Lab Private Ltd15,548$289.0K0.03%
Engineers Gate Manager LP14,500$270.0K0.02%
Blueshift Asset Management, LLC13,189$245.0K0.01%
Quantbot Technologies LP900$16.0K0.00%

Sold out (26)

Institutions that held Sutro Biopharma, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.